Stigmasterol mitigates estrogen-deficiency-induced osteoporosis through inhibition of phosphorylated p65 and MAPK signaling pathways.

Front Pharmacol · 2024 · PMC11685749 · PMID 39741634

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

a decreasing trendno p-value reported

Compared to the RANKL model group, phosphorylation of ERK exhibited a decreasing trend at the 15 and 45-min marks.

also in 47,180 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.